A record of what Sridhar Sivaram said publicly, with the source. Not advice.
Pending — not yet graded
“Favors the pharmaceuticals sector, seeing significant long-term opportunities in exports, particularly in GLP-1 drugs and contract development and manufacturing (CDMO). He expects the entire value chain to benefit from patent expiries globally.”
Pharmaceuticals SectorBullishCalled 06 Jul 2026
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Sridhar Sivaram’s full track record